Ionis Pharmaceuticals (IONS) news
Recent news
Ionis Pharmaceuticals, Inc. (IONS.O): BMO initiates coverage with market perform rating; price target $60
Ionis Pharmaceuticals, Inc. (IONS.O) has recently attracted attention as BMO Capital Markets initiated coverage of the stock with a "Market Perform" rating and price target of $60. This assessment positions Ionis as a "show-me story," indicating that the firm believes the company has potential but…
AInvest Wire · Aug 19, 2026Ionis Pharma shares drop 8.2% premarket
Ionis Pharmaceuticals Inc. (IONS) shares fell 8.2% in premarket trading on July 22, 2026, following the release of its second-quarter financial results [1]. The company reported revenue of $298 million for the quarter, representing a 12% increase compared to the same period in 2025. Despite the…
AInvest Wire · Jul 22, 2026Ionis Pharmaceuticals Inc: Guggenheim cuts target price to $89 from $106
Guggenheim Securities has revised its price target for Ionis Pharmaceuticals Inc (NASDAQ: IONS), reducing it to $89 from a previous $106, according to a recent report [1]. The adjustment reflects a reassessment of the company’s near-term outlook and market dynamics. Ionis, a biotechnology firm…
AInvest Wire · Jul 21, 2026Alnylam Pharmaceuticals (ALNY) falls 5.41% intraday after competitor trial failure
Alnylam Pharmaceuticals (ALNY) shares fell 5.41% in intraday trading following the announcement by Ionis Pharmaceuticals and AstraZeneca that their Phase 3 trial for eplontersen did not meet its primary efficacy endpoint in treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The…
AInvest Wire · Jul 10, 2026Ionis Pharmaceuticals Inc: H.C. Wainwright cuts target price to $125 from $130
Ionis Pharmaceuticals, Inc. (IONS) recently saw its price target adjusted by H.C. Wainwright, which cut its target to $125 from $130 while maintaining a Buy rating. This follows the FDA’s approval of TRYNGOLZA (olezarsen), the first therapy to reduce triglycerides and the risk of acute pancreatitis…
AInvest Wire · Jul 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.